Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 19/20 | 0.87 |
| ▸ | KDR | P35968 | 18/20 | 0.87 |
| ▸ | ERBB2 | P04626 | 18/20 | 0.87 |
| ▸ | EPHB4 | P54760 | 17/20 | 0.87 |
| ▸ | FLT1 | P17948 | 13/20 | 0.87 |
| ▸ | EGFR | P00533 | 4/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1224701 | 0.93 | EPHA2 (1.00) | EPHA2KDRERBB2EPHB4FLT1 | |
| SCHEMBL14147677 | 0.93 | EPHA2 (0.84) | EPHA2KDRERBB2EPHB4FLT1 | |
| SCHEMBL1225038 | 0.92 | EPHA2 (1.00) | EPHA2KDRERBB2EPHB4FLT1 | |
| SCHEMBL1225039 | 0.92 | EPHA2 (1.00) | EPHA2KDRERBB2EPHB4FLT1 | |
| SCHEMBL13589116 | 0.92 | EPHA2 (1.00) | EPHA2KDRERBB2EPHB4FLT1 | |
| SCHEMBL906945 | 0.89 | EPHA2 (1.00) | EPHA2KDRERBB2EPHB4FLT1 | |
| SCHEMBL1793282 | 0.88 | KDR (1.00) | EPHA2KDRERBB2EPHB4FLT1 | |
| SCHEMBL1225633 | 0.88 | KDR (1.00) | EPHA2KDRERBB2EPHB4FLT1 | |
| SCHEMBL12898312 | 0.88 | KDR (1.00) | EPHA2KDRERBB2EPHB4FLT1 | |
| SCHEMBL1224888 | 0.88 | KDR (1.00) | EPHA2KDRERBB2EPHB4FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | EPHA2 2/4885KDR 17/4885ERBB2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.